Lupus Nephritis

🌍 Did you know that only four African countries have updated their National Essential Medicines Lists since 2021 to include modern treatments for rheumatic diseases in children? This gap highlights the urgent need for policy development and innovative financing strategies. Let's work together to ensure every child has access to the medicines they need. #SyenzaNews #Healthcare #RheumaticDiseases #EssentialMedicines #UniversalHealthCoverage 📢 Learn more about how we can improve access to essential medicines for children with rheumatic diseases in Africa. Read our latest article!

🌟 #SyenzaNews 🌟 Discover how PAFLAR is advancing paediatric rheumatology care in Africa! From empowering Therapeutic Patient Education workshops to inspiring stories of dedicated professionals, learn about the strides being made to improve the lives of children with rheumatic diseases. 🌍👩‍⚕️👨‍⚕️ #PaediatricRheumatology #HealthcareInnovation #PatientEducation #MedicalAdvocacy #GlobalHealth #JIA 🩺 Together, we can make a difference!

🌟Enhancing Early Diagnosis and Access to Care for Juvenile Idiopathic Arthritis 🌟 Delays in diagnosing and treating juvenile idiopathic arthritis (JIA) can significantly impact the quality of life for children and young people. Our latest article explores the factors contributing to these delays and suggests strategies to facilitate earlier diagnosis and prompt referral to paediatric rheumatology care. Learn more about how education, awareness, and streamlined referral pathways can improve outcomes for CYP with JIA. Read the full article here #SyenzaNews #JuvenileArthritis #Healthcare #PaediatricRheumatology #EarlyDiagnosis #PatientCare

Discover the role of #Anifrolumab in managing systemic lupus erythematosus (SLE). This breakthrough treatment not only enhances patients' quality of life but also reduces healthcare costs. Read our latest article to learn more. #SLE #HealthcareInnovation #Cost-Effectiveness 📚🔬💊👩‍⚕️👨‍⚕️

Uncover the economic implications of End-Stage Renal Disease (ESRD) in Sub-Saharan Africa, with a focus on Sudan. Learn how the disease affects patients, caregivers, and the wider society. Read more here: #ESRD #HealthEconomics #KidneyDisease 🌍💰🏥

🔬 Discover the crucial role of #TPMT and #NUDT15 in #ThiopurineTherapy in our latest article. Understand why genetic testing is essential to optimise treatment, reduce risk, and save costs. Read now ➡️ #Pharmacogenetics #CostEffectiveness #PharmaMarketAccess

Discover a new cost-effective approach to managing fatigue in Inflammatory Rheumatic Diseases. Our latest article reveals the economic and health benefits of personalised exercise programmes. Read more here 👉 #Healthcare #RheumaticDiseases #FatigueManagement

Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.